Literature DB >> 17131382

Animal models for chronic lymphocytic leukemia.

Yuri Pekarsky1, Nicola Zanesi, Rami I Aqeilan, Carlo M Croce.   

Abstract

B-cell chronic lymphocytic leukemia (B-CLL), the most common leukemia in the Western world, results from an expansion of a rare population of CD5+ mature B-lymphocytes. Although clinical features and genomic abnormalities in B-CLL have been studied in considerable detail, the molecular mechanisms underlying disease development has remained unclear until recently. In the last 4 years, several transgenic mouse models for B-CLL were generated. Investigations of these mouse models revealed that deregulation of three pathways, Tcl1-Akt pathway, TNF-NF-kB pathway, and Bcl2-mediated anti-apoptotic pathway, result in the development of B-CLL. While deregulation of TCL1 alone caused a B-CLL phenotype in mice, overexpression of Bcl2 required aberrantly activated TNF-NF-kB pathway signaling to yield the disease phenotype. In this article, we present what has been learned from mice with B-CLL phenotype and how these mouse models of B-CLL were used to test therapeutic treatments for this common leukemia. c 2006 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2007        PMID: 17131382     DOI: 10.1002/jcb.21147

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  21 in total

Review 1.  Molecular basis of CLL.

Authors:  Yuri Pekarsky; Nicola Zanesi; Carlo M Croce
Journal:  Semin Cancer Biol       Date:  2010-09-21       Impact factor: 15.707

2.  Tcl1 interacts with Atm and enhances NF-κB activation in hematologic malignancies.

Authors:  Eugenio Gaudio; Riccardo Spizzo; Francesco Paduano; Zhenghua Luo; Alexey Efanov; Alexey Palamarchuk; Amanda S Leber; Mohamed Kaou; Nicola Zanesi; Arianna Bottoni; Stefan Costinean; Laura Z Rassenti; Tatsuya Nakamura; Thomas J Kipps; Rami I Aqeilan; Yuri Pekarsky; Francesco Trapasso; Carlo M Croce
Journal:  Blood       Date:  2011-11-07       Impact factor: 22.113

3.  Silencing of the inhibitor of DNA binding protein 4 (ID4) contributes to the pathogenesis of mouse and human CLL.

Authors:  Shih-Shih Chen; Rainer Claus; David M Lucas; Lianbo Yu; Jiang Qian; Amy S Ruppert; Derek A West; Katie E Williams; Amy J Johnson; Fred Sablitzky; Christoph Plass; John C Byrd
Journal:  Blood       Date:  2010-11-22       Impact factor: 22.113

4.  13q14 deletions in CLL involve cooperating tumor suppressors.

Authors:  Alexey Palamarchuk; Alexey Efanov; Natalya Nazaryan; Urmila Santanam; Hansjuerg Alder; Laura Rassenti; Thomas Kipps; Carlo M Croce; Yuri Pekarsky
Journal:  Blood       Date:  2010-01-13       Impact factor: 22.113

Review 5.  miR deregulation in CLL.

Authors:  Veronica Balatti; Yuri Pekarky; Lara Rizzotto; Carlo M Croce
Journal:  Adv Exp Med Biol       Date:  2013       Impact factor: 2.622

6.  MicroRNAs in mouse models of lymphoid malignancies.

Authors:  Nicola Zanesi; Yuri Pekarsky; Francesco Trapasso; George Calin; Carlo M Croce
Journal:  J Nucleic Acids Investig       Date:  2010

7.  Accumulation of B1-like B cells in transgenic mice over-expressing catalytically inactive RAG1 in the periphery.

Authors:  Ashraf E Hassaballa; Victoria L Palmer; Dirk K Anderson; Michele D Kassmeier; Vincent K Nganga; Kevin W Parks; Dustin L Volkmer; Greg A Perry; Patrick C Swanson
Journal:  Immunology       Date:  2011-12       Impact factor: 7.397

8.  Chronic lymphocytic leukemia and regulatory B cells share IL-10 competence and immunosuppressive function.

Authors:  D J DiLillo; J B Weinberg; A Yoshizaki; M Horikawa; J M Bryant; Y Iwata; T Matsushita; K M Matta; Y Chen; G M Venturi; G Russo; J P Gockerman; J O Moore; L F Diehl; A D Volkheimer; D R Friedman; M C Lanasa; R P Hall; T F Tedder
Journal:  Leukemia       Date:  2012-07-13       Impact factor: 11.528

9.  The TCL1A oncoprotein interacts directly with the NF-kappaB inhibitor IkappaB.

Authors:  Virginie Ropars; Gilles Despouy; Marc-Henri Stern; Serge Benichou; Christian Roumestand; Stefan T Arold
Journal:  PLoS One       Date:  2009-08-10       Impact factor: 3.240

10.  Akt is activated in chronic lymphocytic leukemia cells and delivers a pro-survival signal: the therapeutic potential of Akt inhibition.

Authors:  Jianguo Zhuang; Stephen F Hawkins; Mark A Glenn; Ke Lin; Gillian G Johnson; Anthony Carter; John C Cawley; Andrew R Pettitt
Journal:  Haematologica       Date:  2009-08-27       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.